Brenig Therapeutics Announces Oral Presentation of Phase 1 Data for BT-267 at AD/PD™ 2026, and Provides Updates on BT-409, its NLRP3 Inhibitor Program

BOSTON, March 17, 2026 — Brenig Therapeutics, Inc. (Brenig), a clinical-stage biotechnology company advancing small-molecule therapies for neurologic diseases, today announced that Tien Dam, MD, Chief Medical Officer, will present interim data from the Company's ongoing Phase 1 clinical trial of BT-267, its novel, brain-penetrant leucine-rich repeat kinase 2 (LRRK2) inhibitor, at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026), being held March 17-21, 2026, in Copenhagen, Denmark.

The presentation will highlight emerging clinical data evaluating the safety, tolerability, pharmacokinetics (PK), and central nervous system (CNS) penetration of BT-267 in healthy volunteers.

Presentation Details

Title: Phase 1 Study of BT-267, a potent, selective, brain-penetrant, and oral small-molecule inhibitor of LRRK2 (ID 3219) Presenter: Tien Dam, MD, Chief Medical Officer, Brenig Therapeutics Symposium 6010: PD and Lewy Body Disorders: From Prevention to Novel Therapies Date/Time: March 21, 2026 | 12:25pm CET Location: Hall A2

"BT-267 was designed to achieve robust and sustained LRRK2 inhibition in the brain, a key driver of Parkinson's disease biology," said Tien Dam, MD, Chief Medical Officer of Brenig Therapeutics. "In our ongoing Phase 1 study, we observe encouraging pharmacokinetic properties, including evidence of meaningful CNS exposure, which we believe may support a best-in-class profile for the LRRK2 inhibitor class. We look forward to sharing these data at AD/PD."

BT-267 is a potent, selective, brain-penetrant inhibitor of LRRK2, a genetically validated target implicated in Parkinson's disease. The ongoing Phase 1 study is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of BT-267 in healthy volunteers.

Pipeline Update: BT-409 (NLRP3 Inhibitor Program)

Brenig also announced that it has dosed healthy volunteers in its Phase 1 clinical trial of BT-409, a brain-penetrant NLRP3 inhibitor targeting neuroinflammation. BT-409 has been well tolerated to date, with no safety signals observed thus far and the study is progressing as planned. The Company believes BT-409 has the potential to be a best-in-class compound with high brain penetration to address a broad range of neuroinflammatory conditions.

About Brenig Therapeutics

Founded in 2021 through a venture creation initiative led by Torrey Pines Investment and OrbiMed, Brenig Therapeutics secured a $65 million Series A financing in July 2024, led by NEA with participation from BioGeneration Ventures, OrbiMed, Torrey Pines, and other U.S.-based healthcare investors. Brenig is dedicated to developing innovative small-molecule therapies to address fundamental disease mechanisms and accelerate clinical translation for neurodegenerative diseases. BT-409 was licensed from Mwyngil Therapeutics.